Literature DB >> 27732700

Understanding the Role of P Values and Hypothesis Tests in Clinical Research.

Daniel B Mark1, Kerry L Lee2, Frank E Harrell3.   

Abstract

P values and hypothesis testing methods are frequently misused in clinical research. Much of this misuse appears to be owing to the widespread, mistaken belief that they provide simple, reliable, and objective triage tools for separating the true and important from the untrue or unimportant. The primary focus in interpreting therapeutic clinical research data should be on the treatment ("oomph") effect, a metaphorical force that moves patients given an effective treatment to a different clinical state relative to their control counterparts. This effect is assessed using 2 complementary types of statistical measures calculated from the data, namely, effect magnitude or size and precision of the effect size. In a randomized trial, effect size is often summarized using constructs, such as odds ratios, hazard ratios, relative risks, or adverse event rate differences. How large a treatment effect has to be to be consequential is a matter for clinical judgment. The precision of the effect size (conceptually related to the amount of spread in the data) is usually addressed with confidence intervals. P values (significance tests) were first proposed as an informal heuristic to help assess how "unexpected" the observed effect size was if the true state of nature was no effect or no difference. Hypothesis testing was a modification of the significance test approach that envisioned controlling the false-positive rate of study results over many (hypothetical) repetitions of the experiment of interest. Both can be helpful but, by themselves, provide only a tunnel vision perspective on study results that ignores the clinical effects the study was conducted to measure.

Entities:  

Year:  2016        PMID: 27732700     DOI: 10.1001/jamacardio.2016.3312

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  19 in total

1.  Programmed Intermittent Epidural Boluses (PIEB) for Maintenance of Labor Analgesia: An Incremental Step Before the Next Paradigm Shift?

Authors:  Brendan Carvalho; Edward T Riley
Journal:  Turk J Anaesthesiol Reanim       Date:  2017-04-01

2.  While modern medicine evolves continuously, evidence-based research methodology remains: how register studies should be interpreted and appreciated.

Authors:  Eleonor Svantesson; Eric Hamrin Senorski; Kurt P Spindler; Olufemi R Ayeni; Freddie H Fu; Jón Karlsson; Kristian Samuelsson
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-08       Impact factor: 4.342

3.  Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.

Authors:  Daniel B Mark; Kevin J Anstrom; Shubin Sheng; Jonathan P Piccini; Khaula N Baloch; Kristi H Monahan; Melanie R Daniels; Tristram D Bahnson; Jeanne E Poole; Yves Rosenberg; Kerry L Lee; Douglas L Packer
Journal:  JAMA       Date:  2019-04-02       Impact factor: 56.272

4.  Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA.

Authors:  Daniel B Mark; John A Spertus; Robert Bigelow; Sophia Anderson; Melanie R Daniels; Kevin J Anstrom; Khaula N Baloch; David J Cohen; Claes Held; Shaun G Goodman; Sripal Bangalore; Derek Cyr; Harmony R Reynolds; Karen P Alexander; Yves Rosenberg; Gregg W Stone; David J Maron; Judith S Hochman
Journal:  Circulation       Date:  2022-03-09       Impact factor: 39.918

5.  Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial.

Authors:  Tristram D Bahnson; Anna Giczewska; Daniel B Mark; Andrea M Russo; Kristi H Monahan; Hussein R Al-Khalidi; Adam P Silverstein; Jeanne E Poole; Kerry L Lee; Douglas L Packer
Journal:  Circulation       Date:  2021-12-22       Impact factor: 39.918

6.  Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.

Authors:  Matthew L Hung; James X Wu; Ning Li; Masha J Livhits; Michael W Yeh
Journal:  JAMA Surg       Date:  2018-12-01       Impact factor: 14.766

7.  Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial.

Authors:  Douglas L Packer; Jonathan P Piccini; Kristi H Monahan; Hussein R Al-Khalidi; Adam P Silverstein; Peter A Noseworthy; Jeanne E Poole; Tristram D Bahnson; Kerry L Lee; Daniel B Mark
Journal:  Circulation       Date:  2021-02-08       Impact factor: 29.690

8.  Association Between Sex and Treatment Outcomes of Atrial Fibrillation Ablation Versus Drug Therapy: Results From the CABANA Trial.

Authors:  Andrea M Russo; Emily P Zeitler; Anna Giczewska; Adam P Silverstein; Hussein R Al-Khalidi; Yong-Mei Cha; Kristi H Monahan; Tristram D Bahnson; Daniel B Mark; Douglas L Packer; Jeanne E Poole
Journal:  Circulation       Date:  2021-01-27       Impact factor: 29.690

9.  Second-generation p-values: Improved rigor, reproducibility, & transparency in statistical analyses.

Authors:  Jeffrey D Blume; Lucy D'Agostino McGowan; William D Dupont; Robert A Greevy
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

10.  Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities.

Authors:  Kevin L Thomas; Hussein R Al-Khalidi; Adam P Silverstein; Kristi H Monahan; Tristram D Bahnson; Jeanne E Poole; Daniel B Mark; Douglas L Packer
Journal:  J Am Coll Cardiol       Date:  2021-07-13       Impact factor: 27.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.